BeiGene Secures $10.5 Billion Deal with Pfizer, Core ADC Data Outperforms, Maintain Overweight

Overview

Morgan Stanley releases meeting minutes focusing on BeiGene's major oncology drug collaboration with Pfizer and key clinical data from the ASCO conference. The report believes that this partnership not only brings substantial upfront payments and potential milestone income to BeiGene but also marks a strategic upgrade for Chinese biotech companies from 'building global influence' to 'preserving global value.' Combined with excellent clinical performance of core product IBl363 and robust cash flow, the institution maintains an 'Overweight' rating and raises the target price to HK$135, implying approximately 67% upside potential.

Core views

The core views of this report revolve around three pillars: 'major deal + quality data + financial stability.' Firstly, in terms of the collaboration with Pfizer, both parties announced a global oncology drug agreement totaling up to $10.5 billion, covering 12 early-stage or de novo development programs. The transaction structure includes four global licenses, four non-China Greater China region licenses, and four co-development and commercialization projects. BeiGene will receive a $650 million upfront payment and has the potential for up to $9.85 billion in milestone payments and royalty revenue. Management expects this upfront payment to be amortized over one to two years. This 'co-development' model allows BeiGene to retain rights in the Greater China region while sharing profits in North America and Europe, significantly enhancing its valuation ceiling. Secondly, in terms of core pipeline data, the latest results for IBl363 (a TIGIT antibody) are impressive. Management presented at ASCO that the optimal first-line treatment regimen is a starting dose of 3mg combined with a maintenance dose of 1.5mg: a single 3mg loading dose can activate the tumor microenvironment, while the 1.5mg maintenance dose reduces interruptions and toxicity. Data show that this regimen achieves an objective response rate (ORR) of 86.4% and complete response rate (cORR) of 81.8% in second-line resistant patients, significantly better than the 42.1% cORR in the 1.5mg-only group; furthermore, grade 3 or higher adverse event incidence was only 65.2%, lower than the 93.1% in the 3mg monotherapy arm. More importantly, the median overall survival (mOS) reached 18.2 months, significantly superior to other ADC comparators, supporting its registration potential and expansion into adenocarcinoma. Finally, from a financial perspective, the company demonstrates strong risk resilience. After the transaction, BeiGene's cash reserves will exceed $4 billion, sufficient to support intensive R&D efforts, with limited recent capital expenditure pressure. This provides ample 'ammunition' for global competition.

Analysis framework

The institutional analysis follows a framework of 'transaction-driven valuation reshaping + data validating business prospects + financial safety net supporting long-term growth.' Step one: by dissecting the amount structure and equity distribution of the Pfizer deal, we argue how this transaction changes the company's business model—from a purely domestic biotech to a platform company with global commercial capabilities—thereby increasing valuation multiples. Step two: using key clinical data from the ASCO conference (such as mOS, ORR, and safety indicators), we validate the global competitiveness of its technology platforms (especially ADC and bispecific antibodies), eliminating market concerns about data validity. Step three: combining balance sheet analysis confirms that the substantial upfront payment improves liquidity enough to cover R&D costs, reducing risks of bankruptcy or dilution, offering certainty for long-term growth. This analytical approach integrates macro industry trends (Chinese pharma going global) with micro company fundamentals (specific pipeline data and financial health), forming a complete investment logic loop.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  The report uses a base-case DCF model for valuation, assuming WACC of 8.8% and perpetual growth rate of 3%.

  This is the most commonly used method for evaluating growth-oriented biopharmaceutical companies, where future expected free cash flows are discounted to current value to determine if the company is undervalued. The report clearly specifies WACC and growth parameters, reflecting quantified assumptions about risk premium and long-term growth potential.

• Industry/Industrial Analysis FrameworkUpstream-Midstream-Downstream Industry Chain Transmission

  By analyzing deal terms (global licensing vs. co-development), assess how Chinese biotech captures value within the industrial chain.

  Traditional Chinese pharmaceutical companies often operate at the upstream R&D level or only license overseas rights. 'Co-development' means deeper involvement in downstream commercial profit-sharing. The report points out that this model moves BeiGene up the valuation ladder, shifting from 'water seller' to 'partner' role.

• Competitive & Strategic FrameworkMoat / competitive advantage

  Use IBl363 clinical data (mOS 18.2 months vs. ADC competitors) to build differentiated competitive advantage.

  In the highly competitive oncology drug space, superior survival data (mOS) is a key factor building product moats. The report contrasts these data to prove the unique advantages of this product over existing ADC therapies, which is the core barrier supporting high valuations.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• BeiGene (1801.HK)

  Core beneficiary, gains substantial funds and technical validation through Pfizer deal, restructure valuation logic.

  Strengths

  Possesses globally competitive core pipelines such as IBl363; strong cash reserves; establishes global partner status via Pfizer deal.

  Weaknesses

  Some data follow-up time is still short (PFS not mature); need to monitor subsequent approval progress and competitive landscape changes.

  Comparison

  Compared to other Chinese biotechs, BeiGene has greater international depth and cash reserves; IBl363 data outperforms similar ADC competitors.

  Risks

  IBl363 may fail in later clinical trials; Pfizer milestone payments may not be achieved; Fast-follow competition intensifies.

Key data

• Pfizer Deal Total Amount$10.5 BillionCovers 12 oncology drug projects, including $650 million upfront payment and up to $9.85 billion in milestone payments
• IBl363 mOS (Second-Line)18.2 Months3mg loading + 1.5mg maintenance regimen, significantly outperforms ADC competitors
• IBl363 ORR (Second-Line)86.4%n=22, compared to 42.1% in 1.5mg-only group showing significant improvement
• IBl363 G3+ TEAE65.2%Better than 93.1% in 3mg monotherapy arm, better safety profile
• Expected Cash Reserves> $4 BillionPost-transaction cash is sufficient to support R&D investment
• Target PriceHK$135Potential upside of 67% compared to current price (HK$80.9)

Impact & implications

This deal and data validation have profound positive implications for BeiGene. Firstly, the $10.5 billion transaction size directly proves the scarcity and commercial value of its assets globally, helping enhance the company’s reputation and financing capacity in international capital markets. Secondly, the excellent data from IBl363 provides solid grounds for further development and commercialization across multiple indications (e.g., adenocarcinoma), potentially accelerating launch timelines and expanding market reach. Lastly, abundant cash flow alleviates concerns about funding risks for biotech firms, allowing them to proceed more confidently with subsequent pipeline R&D and even pursue more M&A activities.

Risks

• Durability of IBl363 efficacy or overall survival data not confirmed globally
• IBl362 or Mazzutide (mazdutide) label expansion falls short of expectations
• Emergence of fast-follow competitors or cautious regulatory stance abroad causing delayed approvals

What to watch

• Further clinical data readouts from IBl363 (especially PFS results)
• Early data progression of IBl343
• Sales ramp speed of Mazzutide
• Whether more deals similar to Eli Lilly/Takeda models emerge